Europe faces a significant challenge in meeting its public health goals, as new data indicates the region risks missing the World Health Organization target to eliminate viral hepatitis as a major public health threat by 2030. According to findings published in Nature and reports tracked by News-Medical, persistent gaps in screening, diagnosis, and treatment delivery across European nations threaten progress against hepatitis B and C.
Viral Hepatitis Trajectory in Europe
Public health authorities track viral hepatitis elimination through specific markers established by the World Health Organization. According to reports from Nature, while several Western European countries have scaled up direct-acting antiviral therapies for hepatitis C, overall regional metrics show lagging screening rates among high-risk populations. The gap between infected individuals and those who receive a confirmed diagnosis remains too wide to achieve the 2030 reduction targets.
Data compiled by News-Medical highlights that marginalized groups, including people who inject drugs and migrants, often encounter structural barriers when trying to access healthcare services. Without targeted outreach and simplified diagnostic pathways, national health systems cannot close these coverage gaps in time.
Diagnostic and Treatment Challenges
Scaling up treatment requires addressing systemic hurdles within primary care networks. As detailed in Nature, many healthcare facilities still rely on multi-step testing procedures that cause patients to drop out of the care cascade before receiving a prescription. Point-of-care testing and reflex testing—where a single blood draw covers both antibody screening and viral load confirmation—remain underutilized in many jurisdictions.
Financing models across various European states also affect drug and vaccine availability. According to News-Medical, budget constraints in public health sectors often limit the widespread procurement of advanced therapeutics and preventative vaccines, particularly in Eastern and Southern European regions.
Public Health Outlook
Reversing current trends requires immediate policy adjustments from national governments and health ministries. As emphasized in assessments from Nature, integrating hepatitis screening into routine primary care and harm reduction programs is essential. Public health experts cited in these analyses stress that unless funding and decentralized care models increase rapidly over the next few years, Europe will fall short of the 2030 elimination milestone.
Keep reading